Skip to main content

Table 2 Treatment steps for the control intervention. More details in relation to the treatment steps are provided in Appendix 1; a detailed decision tree is shown in Appendix 2

From: Reducing Asthma Attacks in Children using Exhaled Nitric Oxide as a biomarker to inform treatment strategy: a randomised trial (RAACENO)

Treatment step Daily ICS dose μg budesonide or equivalent Delivery device used prior to enrolment used after enrolment
1 0 No ICS Short-acting beta-agonist (SABA) as required only
2 200 Very low dose ICS Budesonide (or equivalent) 100 μg twice daily plus SABA
3 400 Low dose ICS Budesonide (or equivalent) 200 μg twice daily plus SABA
4 400 ICS + long-acting beta-agonist (LABA) combination inhaler Budesonide (or equivalent) 200 μg twice daily plus SABA and LABA (dose depending on ICS molecule used)
5 400 Add on leukotriene receptor antagonist (LTRA)‡ Budesonide (or equivalent) 200 μg twice daily plus SABA, LABA and LTRA
6 800 High dose ICS Budesonide (or equivalent) 400 μg twice daily plus SABA, LABA (dose depending on ICS molecule used) and LTRA
7
For 12–16 year olds (go to step 8 for children < 12)
1600 High dose ICS Budesonide (or equivalent) 800 μg twice daily plus SABA, LABA and LTRA
8    Refer for specialist opinion